Clinical Trial Update: 24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME. [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing systemic VEGF levels after ranibizumab versus aflibercept in diabetic macular edema was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Aflibercept (Aflibercept)
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Visual Impairment Due to Diabetic Macular Edema | Phase 4 | Status: WITHDRAWN